These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35634509)

  • 1. Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer.
    Liu L; Shi Y; Lai Q; Huang Y; Jiang X; Liu Q; Huang Y; Xia Y; Xu D; Jiang Z; Tu W
    Front Endocrinol (Lausanne); 2022; 13():865909. PubMed ID: 35634509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
    Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
    Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
    Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
    JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
    Zhou C; Duan D; Liu S
    Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.
    Jeon YW; Ahn YE; Chung WS; Choi HJ; Suh YJ
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e167-73. PubMed ID: 24289279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Potential Four-Gene Signature and Nomogram for Predicting the Overall Survival of Papillary Thyroid Cancer.
    Ding Y; Li P; Wang W; Liu F
    Dis Markers; 2022; 2022():8735551. PubMed ID: 36193505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
    Guo H; Zhang N; Hu Y; Zhang F; Huang T; Shen N
    Front Endocrinol (Lausanne); 2023; 14():1158581. PubMed ID: 37664843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer.
    Wang X; Zhu J; Li Z; Wei T
    PLoS One; 2020; 15(6):e0234843. PubMed ID: 32542018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 14. A Metabolic-associated Nomogram Predicts Recurrence Survival of Thyroid Cancer.
    Xi ZH; Ma XX; Chen HY; Yu YH; Li L; Huang T
    Curr Med Sci; 2021 Oct; 41(5):1004-1011. PubMed ID: 34510328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.
    Jin T; Ge L; Chen J; Wang W; Zhang L; Ge M
    PeerJ; 2023; 11():e15592. PubMed ID: 37361050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
    Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
    Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway.
    Liu C; Feng Z; Chen T; Lv J; Liu P; Jia L; Zhu J; Chen F; Yang C; Deng Z
    Cell Cycle; 2019 Jan; 18(2):167-203. PubMed ID: 30596336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
    Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.
    Xia Y; Jiang X; Huang Y; Liu Q; Huang Y; Zhang B; Mei Z; Xu D; Shi Y; Tu W
    Front Endocrinol (Lausanne); 2022; 13():895428. PubMed ID: 35757399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.